NCT07432178 2026-02-25
CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）
Fudan University
Phase 3 Not yet recruiting
Clinical Trials
11 trialsNCT07423611 2026-02-20
RACE
Fudan University
Phase 2 Not yet recruiting
NCT06996093 2025-05-30
Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
Fudan University
Phase 3 Not yet recruiting
NCT06684054 2024-11-12
STFREiYTNBC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not yet recruiting
NCT06470633 2024-06-24
To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06404463 2024-05-08
QUEEN-Neo
Fudan University
Phase 2 Not yet recruiting
NCT06371807 2024-04-17
KEYPARTNER
Fundacao Champalimaud
Phase 2 Not yet recruiting
NCT06229067 2024-01-29
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT05287308 2022-03-31
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study
ChineseAMS
Phase NA Not yet recruiting
NCT05131893 2021-11-23
Neoadjuvant Treatment of Breast Cancer
National Institute of Oncology, Hungary
Not yet recruiting
NCT04137640 2021-07-20
Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy
Shengjing Hospital
Phase 4 Not yet recruiting